We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
+34.21%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$8.57B
AUM Growth
+$1.33B
(+18%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
6.44%
Top 10 Holdings %
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$238M |
| 2 |
Vera Therapeutics
VERA
|
+$188M |
| 3 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$170M |
| 4 |
Viking Therapeutics
VKTX
|
+$160M |
| 5 |
MacroGenics
MGNX
|
+$93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$287M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$262M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$135M |
| 4 |
Structure Therapeutics
GPCR
|
+$95.1M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$39.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.24% |
| 2 | Miscellaneous | 4.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$21.5B
| $657M | 7.66% |
2,858,888
| – | – |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $653M | 7.62% |
11,111,111
| – | – |
|
3
Ascendis Pharma A/S
ASND
$15.8B
| $600M | 6.99% |
3,966,666
+211,111
| +6% | +$30.1M |
|
4
Sarepta Therapeutics
SRPT
$2.19B
| $562M | 6.56% |
4,344,444
| – | – |
|
5
Madrigal Pharmaceuticals
MDGL
$12.1B
| $519M | 6.06% |
1,944,444
+55,556
| +3% | +$13.1M |
|
6
argenx
ARGX
$61.3B
| $488M | 5.69% |
1,238,467
+3,900
| +0.3% | +$1.51M |
|
7
Krystal Biotech
KRYS
$9.97B
| $455M | 5.3% |
2,555,555
-10,000
| -0.4% | -$1.39M |
|
8
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $408M | 4.76% |
4,300,000
-144,444
| -3% | -$13.4M |
|
9
BioMarin Pharmaceuticals
BMRN
$12.5B
| $381M | 4.45% |
4,365,000
+65,000
| +2% | +$5.82M |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $323M | 3.76% |
27,400,000
| – | – |
|
|
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $319M | 3.73% |
7,555,555
| – | – |
|
|
12
Viking Therapeutics
VKTX
$3.49B
| $294M | 3.43% |
+3,590,000
| New | +$160M |
|
|
13
Arrowhead Research
ARWR
$9.98B
| $245M | 2.85% |
8,555,555
+7,425,555
| +657% | +$238M |
|
14
Xenon Pharmaceuticals
XENE
$5.45B
| $244M | 2.85% |
5,666,666
| – | – |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
| $229M | 2.67% |
+5,775,000
| New | +$170M |
|
|
16
Vera Therapeutics
VERA
$2.43B
| $227M | 2.65% |
+5,265,000
| New | +$188M |
|
17
Iovance Biotherapeutics
IOVA
$4.24B
| $173M | 2.02% |
11,700,000
+5,000,000
| +75% | +$58.2M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $171M | 2% |
2,475,000
+219,445
| +10% | +$15.1M |
|
19
Kymera Therapeutics
KYMR
$9.41B
| $156M | 1.82% |
3,888,888
+113,888
| +3% | +$4.07M |
|
|
RNAM
20
DELISTED
Avidity Biosciences
RNAM
| $149M | 1.73% |
5,825,000
+3,315,000
| +132% | +$52M |
|
21
MoonLake Immunotherapeutics
MLTX
$1.04B
| $130M | 1.51% |
2,580,000
| – | – |
|
22
Syndax Pharmaceuticals
SNDX
$1.62B
| $100M | 1.17% |
4,222,222
| – | – |
|
|
23
MacroGenics
MGNX
$257M
| $90.5M | 1.06% |
+6,150,000
| New | +$93M |
|
24
Kura Oncology
KURA
$1.01B
| $82.1M | 0.96% |
3,850,000
+870,000
| +29% | +$16.9M |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$503M
| $78.8M | 0.92% |
+12,345,678
| New | +$77M |
|
Similar funds
GI
AIM
BEI
VNIM
MF
MC
GJL
LCAM
Avoro Capital Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Avoro Capital Advisors held 53 positions worth $8.57B, up 18% from $7.24B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Avoro Capital Advisors deployed $552M of net new capital in Q1 2024, opening 11 new positions and adding to 15 existing holdings. Its largest new stake was Vera Therapeutics: 5,265,000 shares worth $227M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $135M trimmed.
- Avoro Capital Advisors's largest Q1 2024 buy was Vera Therapeutics: 5,265,000 shares worth $227M.
- Avoro Capital Advisors added most to Arrowhead Research in Q1 2024, an estimated $238M increase.
- Avoro Capital Advisors's biggest Q1 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $135M.
- Avoro Capital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $287M.
- Avoro Capital Advisors's ten largest holdings make up 59% of its $8.57B portfolio in Q1 2024.
- Avoro Capital Advisors opened 11 new positions and closed 7 in Q1 2024.
- Avoro Capital Advisors's portfolio value rose 18% quarter-over-quarter to $8.57B.
Based on Avoro Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.